Topical political pictures make way for less-specific fare
TORONTO -- At this year's Toronto International Film Festival, the war movies ar all wearing camouflage.
Last twelvemonth, topical political pictures wish "Rendition" and "In the Valley of Elah" came into the Toronto with a head of steam and leftfield in a cloud of dust. This time some, although in that respect is some other onslaught of films with war themes coming to the fest -- which kicks off Thursday night with Canadian filmmaker Paul Gross' World War I saga "Passchendaele" -- they are being billed as everything simply war movies.
Where the 2007 crop sought to mine topicality, producers and publicists are placement their new titles as movies that could just as well be occurrence in any other time or place.
"This movie is not well-nigh the Iraq war. It's an action-adventure movie that happens to be set in Iraq," producer Nic Chartier aforesaid of his film "The Hurt Locker." Directed by Kathryn Bigelow, the film, which focuses on an Army squad in Iraq that must defuse a dangerous bomb in a crowded city, will be seeking a U.S. distribution deal. "This could have been the British and the IRA. It could have been anywhere, in truth," Chartier said.
The cool Toronto reception and subsequent boxoffice bath taken by last year's movies might get stopped some from unspooling war-themed films. But given production imprison time and filmmakers' belief that there are stories still untold, a grouping of war-inflected titles rides into the festival that begins Thursday at Roy Thompson Hall.
Another of those films, "The Lucky Ones," a Tim Robbins-Rachel McAdams tale of U.S. soldiers recently returned from the Middle East, has as well sought to hit a different note. The picture's trailer and ad campaigns emphasize drollery and comradeship and, with a Sarah McLachlan ballad, it has a softer feel that might appeal to women.
"Iraq is a lousy word in film marketing right now," said Roadside Attractions co-topper Howard Cohen, who is distributing the picture, which has been held for a Sept. 26 spillage in hopes that the zeitgeist might change, fashioning the plastic film more marketable.
"Our goal, in the deuce seconds you have to communicate this to people, is to show that this is not about the warfare in Iraq. It's around American fellowship and how we treat people."
To some degree, the movies indeed represent a new wave.
Festival programmer Jane Schoettle noted, "(These) films are not necessarily about the war itself, just rather the war is a circumstance. Films like 'The Lucky Ones' and 'Hurt Locker' are victimisation the contexts of the war to tell more personal stories."
More specialized fare also contains Middle Eastern themes. The somber "Stoning of Soraya M," a feature from the producers behind "The Passion of the Christ," is a visceral film about the mistreatment of women in Iran. Sony Classics' "Adoration," the Atom Egoyan drama that debuted in Cannes, addresses Islamic terrorism.
But the movies volition face obstacles, at least perceptually. Even without battle scenes, attempts to do movies about how we live nowadays could be doomed by the problem of besides much relevance.
"When you make a flick, you try to be distinctive," the Film Department's Mark Gill said. "Unfortunately, what's beaten you to it is every hour, on the hour, on your wireless, on television, in the paper, on the Internet, is the Iraq war."
And one person behind a Toronto war film terminal year aforesaid that they were "questioning that these (new) movies will do any better."
Still, filmmakers ar hoping that new elements, and some other year of distance, volition overcome that skepticism. But the evidence has still to acquaint itself. As one fest insider aforementioned, "Everyone is still wait for the one to be embraced."
More info
Saturday, 6 September 2008
Wednesday, 27 August 2008
Human Genome Sciences Completes Enrollment In Randomized Phase 2 Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer
�Human Genome
Sciences, Inc. (Nasdaq: HGSI) announced that it has completed the
enrollment and initial dosing of patients in a randomized Phase 2 run of
HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents
paclitaxel and carboplatin as first-line therapy in advanced non-small cell
lung cancer (NSCLC).
"There is an pressing medical motive for effective treatment options for
not small cell lung cancer because current treatment strategies have merely
a minimal impact on survival," said Joachim von Pawel, M.D., a head
investigator in the study from the Asklepios Fachkliniken Munchen-Gauting,
Germany. "The legal age of patients who are newly diagnosed with non-small
cell lung cancer let locally ripe or metastatic disease that is
currently incurable. We look forth to evaluating the potential of
mapatumumab plus chemotherapy to offer a unexampled approach to the first-line
treatment of this venomous disease."
The NSCLC visitation is a randomized, multi-center, open-label Phase 2 study
to judge the efficaciousness and safety of HGS-ETR1 in combination with
carboplatin and paclitaxel as first-line therapy in the discussion of
advanced non-small cell lung crab (Stage IIIB or IV). 111 patients have
been randomly assigned to one of troika treatment groups and treated with
either the two-agent combination of carboplatin and paclitaxel or the
three-agent combination of carboplatin, paclitaxel, and HGS-ETR1 at either
10 mg/kg or 30 mg/kg. HGS announced the initiation of the NSCLC trial In
December 2007.
"A growing body of preclinical data suggests that combining HGS-ETR1
with chemotherapy agents could be an effective access to the treatment of
a number of malignancies, including non-small cell lung cancer," aforementioned
Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research -
Oncology, HGS. "HGS-ETR1 is the most advanced of any ware in development
that targets the TRAIL apoptotic footpath. The NSCLC study is one of three
on-going HGS trials designed to evaluate combinations of HGS-ETR1 with
chemotherapeutical agents for the discourse of specific cancers."
About the HGS-ETR1 Proof-of-Concept Trials
The HGS-ETR1 proof-of-concept phase includes three randomised trials to
evaluate its potential in combination with chemotherapy for the treatment
of specific cancers:
-- Randomization and initial dosing of patients in the NSCLC subject have
now been completed.
-- In July 2008, HGS initiated dosing in the safety lead-in to a
randomised Phase 2 trial of HGS-ETR1 in combination with Nexavar
(sorafenib) in patients with advanced hepatocellular cancer, which accounts
for 80-90% of all liver cancers.
-- The Company expects to have initial information available in the third gear
quarter of 2008 from a randomised Phase 2 trial of HGS-ETR1 in combination
with Velcade (bortezomib) in sophisticated multiple myeloma. Patients in the
multiple myeloma study will carry on on handling until the progression of
disease.
These three trials, taken together, will accompaniment a decision on whether
to advance HGS-ETR1 to Phase 3 development. It also is possible that a
sufficiently positive issue from whatsoever one of the trials could trail to a
Phase 3 decision for that specific indication.
About Non-Small Cell Lung Cancer
Non-small cell lung cancer accounts for around 75-80% of all
lung cancers. It is estimated that more than 170,000 new cases and more
than 160,000 deaths occur annually in the United States alone. It is
currently the leading cause of genus Cancer death in the U.S. in both men and
women.
About HGS-ETR1
HGS-ETR1 (mapatumumab) is an agonistic human monoclonal antibody that
directly induces cancer cell death by specifically cover to and
activating the protein known as TRAIL receptor 1. Using genomic techniques,
HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1
antibody was generated by HGS through quislingism with Cambridge Antibody
Technology. HGS is developing HGS-ETR1 as a potential treatment for a broad
compass of cancers.
About Human Genome Sciences
The mission of HGS is to practice great science and great medicine to
bring innovative drugs to patients with unmet medical needs.
The HGS clinical development grapevine includes novel drugs to treat
hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated
diseases. The Company's primary focus is rapid progress toward the
commercialization of its two key lead drugs, Albuferon(R) (albinterferon
alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase
3 clinical trials of both drugs are on-going.
ABthrax(TM) (raxibacumab) is in late-stage development for the
treatment of inhalation anthrax, and the Company is on track to start the
pitch in fall 2008 of 20,000 doses of ABthrax to the Strategic National
Stockpile under a contract entered into with the U.S. Government in June
2006. HGS likewise has three drugs in clinical development for the treatment of
cancer, including two TRAIL receptor antibodies and a small-molecule
antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has
substantial financial rights to certain products in the GSK clinical
development pipeline.
HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are
trademarks of Human Genome Sciences, Inc.
SAFE HARBOR STATEMENT
This annunciation contains modern statements inside the
import of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. The
forward-looking statements are based on Human Genome Sciences' current
design, belief and expectations. These statements ar not guarantees of
future performance and are topic to certain risks and uncertainties that
are difficult to auspicate. Actual results may differ materially from these
modern statements because of the Company's unproved business
model, its habituation on raw technologies, the uncertainty and timing of
clinical trials, the Company's ability to develop and commercialize
products, its dependence on collaborators for services and revenue, its
solid indebtedness and lease obligations, its changing requirements
and costs associated with facilities, intense competition, the dubiety
of patent and intellectual property protection, the Company's dependence on
key direction and headstone suppliers, the uncertainty of regulation of
products, the impact of future alliances or transactions and other risks
described in the Company's filings with the Securities and Exchange
Commission. In addition, the Company will persist in to face risks related to
beast and human testing, to the manufacture of ABthrax and to FDA
concurrency that ABthrax meets the requirements of the ABthrax contract. If
the Company is ineffectual to forgather the production requirements associated with the
ABthrax get, the U.S. government will not be required to reimburse the
Company for the costs incurred or to purchase any ABthrax doses, and we
testament not get any of the expected revenues relative to ABthrax. Existing
and prospective investors are cautioned not to place undue reliance on
these advanced statements, which speak only as of today's date. 182% Genome Sciences undertakes no obligation to update or retool the
information contained in this proclamation whether as a resolution of new
information, future events or circumstances or otherwise.
Human Genome Sciences, Inc
http://www.hgsi.com
View drug information on Nexavar; Velcade.
More info
Sciences, Inc. (Nasdaq: HGSI) announced that it has completed the
enrollment and initial dosing of patients in a randomized Phase 2 run of
HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents
paclitaxel and carboplatin as first-line therapy in advanced non-small cell
lung cancer (NSCLC).
"There is an pressing medical motive for effective treatment options for
not small cell lung cancer because current treatment strategies have merely
a minimal impact on survival," said Joachim von Pawel, M.D., a head
investigator in the study from the Asklepios Fachkliniken Munchen-Gauting,
Germany. "The legal age of patients who are newly diagnosed with non-small
cell lung cancer let locally ripe or metastatic disease that is
currently incurable. We look forth to evaluating the potential of
mapatumumab plus chemotherapy to offer a unexampled approach to the first-line
treatment of this venomous disease."
The NSCLC visitation is a randomized, multi-center, open-label Phase 2 study
to judge the efficaciousness and safety of HGS-ETR1 in combination with
carboplatin and paclitaxel as first-line therapy in the discussion of
advanced non-small cell lung crab (Stage IIIB or IV). 111 patients have
been randomly assigned to one of troika treatment groups and treated with
either the two-agent combination of carboplatin and paclitaxel or the
three-agent combination of carboplatin, paclitaxel, and HGS-ETR1 at either
10 mg/kg or 30 mg/kg. HGS announced the initiation of the NSCLC trial In
December 2007.
"A growing body of preclinical data suggests that combining HGS-ETR1
with chemotherapy agents could be an effective access to the treatment of
a number of malignancies, including non-small cell lung cancer," aforementioned
Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research -
Oncology, HGS. "HGS-ETR1 is the most advanced of any ware in development
that targets the TRAIL apoptotic footpath. The NSCLC study is one of three
on-going HGS trials designed to evaluate combinations of HGS-ETR1 with
chemotherapeutical agents for the discourse of specific cancers."
About the HGS-ETR1 Proof-of-Concept Trials
The HGS-ETR1 proof-of-concept phase includes three randomised trials to
evaluate its potential in combination with chemotherapy for the treatment
of specific cancers:
-- Randomization and initial dosing of patients in the NSCLC subject have
now been completed.
-- In July 2008, HGS initiated dosing in the safety lead-in to a
randomised Phase 2 trial of HGS-ETR1 in combination with Nexavar
(sorafenib) in patients with advanced hepatocellular cancer, which accounts
for 80-90% of all liver cancers.
-- The Company expects to have initial information available in the third gear
quarter of 2008 from a randomised Phase 2 trial of HGS-ETR1 in combination
with Velcade (bortezomib) in sophisticated multiple myeloma. Patients in the
multiple myeloma study will carry on on handling until the progression of
disease.
These three trials, taken together, will accompaniment a decision on whether
to advance HGS-ETR1 to Phase 3 development. It also is possible that a
sufficiently positive issue from whatsoever one of the trials could trail to a
Phase 3 decision for that specific indication.
About Non-Small Cell Lung Cancer
Non-small cell lung cancer accounts for around 75-80% of all
lung cancers. It is estimated that more than 170,000 new cases and more
than 160,000 deaths occur annually in the United States alone. It is
currently the leading cause of genus Cancer death in the U.S. in both men and
women.
About HGS-ETR1
HGS-ETR1 (mapatumumab) is an agonistic human monoclonal antibody that
directly induces cancer cell death by specifically cover to and
activating the protein known as TRAIL receptor 1. Using genomic techniques,
HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1
antibody was generated by HGS through quislingism with Cambridge Antibody
Technology. HGS is developing HGS-ETR1 as a potential treatment for a broad
compass of cancers.
About Human Genome Sciences
The mission of HGS is to practice great science and great medicine to
bring innovative drugs to patients with unmet medical needs.
The HGS clinical development grapevine includes novel drugs to treat
hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated
diseases. The Company's primary focus is rapid progress toward the
commercialization of its two key lead drugs, Albuferon(R) (albinterferon
alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase
3 clinical trials of both drugs are on-going.
ABthrax(TM) (raxibacumab) is in late-stage development for the
treatment of inhalation anthrax, and the Company is on track to start the
pitch in fall 2008 of 20,000 doses of ABthrax to the Strategic National
Stockpile under a contract entered into with the U.S. Government in June
2006. HGS likewise has three drugs in clinical development for the treatment of
cancer, including two TRAIL receptor antibodies and a small-molecule
antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has
substantial financial rights to certain products in the GSK clinical
development pipeline.
HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are
trademarks of Human Genome Sciences, Inc.
SAFE HARBOR STATEMENT
This annunciation contains modern statements inside the
import of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. The
forward-looking statements are based on Human Genome Sciences' current
design, belief and expectations. These statements ar not guarantees of
future performance and are topic to certain risks and uncertainties that
are difficult to auspicate. Actual results may differ materially from these
modern statements because of the Company's unproved business
model, its habituation on raw technologies, the uncertainty and timing of
clinical trials, the Company's ability to develop and commercialize
products, its dependence on collaborators for services and revenue, its
solid indebtedness and lease obligations, its changing requirements
and costs associated with facilities, intense competition, the dubiety
of patent and intellectual property protection, the Company's dependence on
key direction and headstone suppliers, the uncertainty of regulation of
products, the impact of future alliances or transactions and other risks
described in the Company's filings with the Securities and Exchange
Commission. In addition, the Company will persist in to face risks related to
beast and human testing, to the manufacture of ABthrax and to FDA
concurrency that ABthrax meets the requirements of the ABthrax contract. If
the Company is ineffectual to forgather the production requirements associated with the
ABthrax get, the U.S. government will not be required to reimburse the
Company for the costs incurred or to purchase any ABthrax doses, and we
testament not get any of the expected revenues relative to ABthrax. Existing
and prospective investors are cautioned not to place undue reliance on
these advanced statements, which speak only as of today's date. 182% Genome Sciences undertakes no obligation to update or retool the
information contained in this proclamation whether as a resolution of new
information, future events or circumstances or otherwise.
Human Genome Sciences, Inc
http://www.hgsi.com
View drug information on Nexavar; Velcade.
More info
Monday, 18 August 2008
Bloc Party announce live webchat
Bloc Party have proclaimed details of their number one ever webchat, which testament take place on Blocparty.com at 7pm on Monday (August 18).
Fans will be able to chat directly with the band, wHO released their comeback single 'Mercury' this week (August 11).
Bloc Party are go under to play the Main Stage at Reading And Leeds Festivals, which takes place on August 22-24. They play Reading on Saturday 23, and Leeds the following day.
Aug 23, 2008 at Richfield Avenue, Festival, Reading -
Aug 24, 2008 at Bramham Park, Leeds -
More info
Fans will be able to chat directly with the band, wHO released their comeback single 'Mercury' this week (August 11).
Bloc Party are go under to play the Main Stage at Reading And Leeds Festivals, which takes place on August 22-24. They play Reading on Saturday 23, and Leeds the following day.
Aug 23, 2008 at Richfield Avenue, Festival, Reading -
Aug 24, 2008 at Bramham Park, Leeds -
More Bloc Party tickets
More info
Friday, 8 August 2008
Posh angry with friend Katie Holmes
London (ANI): Victoria Beckham is reportedly livid over the fact that Katie Holmes has ripped of her signature cropped hair dubbed the 'Pob'.
And, the person who's listening to Posh pent up anger with Katie is pint-sized Hollywood pal Eva Longoria, who's sporting a short crop herself these days, looking at more like the Spice Girl every day. The twosome reportedly met at the Desperate Housewife's LA nosherie Beso over the weekend and it seems Posh is convinced that Cruise's married woman got her 'Pob' precisely to upstage her.
"When she arrived in LA, Victoria matte up she was equal to any sensation. But with the failure of the Spice Girls reunion and David's faltering career, she is terrified everyone's losing interest in brand Beckham,"
More info
And, the person who's listening to Posh pent up anger with Katie is pint-sized Hollywood pal Eva Longoria, who's sporting a short crop herself these days, looking at more like the Spice Girl every day. The twosome reportedly met at the Desperate Housewife's LA nosherie Beso over the weekend and it seems Posh is convinced that Cruise's married woman got her 'Pob' precisely to upstage her.
"When she arrived in LA, Victoria matte up she was equal to any sensation. But with the failure of the Spice Girls reunion and David's faltering career, she is terrified everyone's losing interest in brand Beckham,"
More info
Tuesday, 1 July 2008
Wednesday, 18 June 2008
Burhan Ocal, Smadj, The Trakya
Artist: Burhan Ocal, Smadj, The Trakya
Genre(s):
Other
Discography:
Oynamaya Geldik / Trakya Dance Party
Year: 2006
Tracks: 12
Monday, 9 June 2008
Sarah Jessica Parker - Parker Press Attention Makes Me Feel Dirty
SARAH JESSICA PARKER feels like New York's "town trollop" because of the chaos caused by the paparazzi photographers who follow her every day.
The actress claims "thuggish" photographers have made a damaging and lasting impact on the lives of her family, and everyone they come into contact with.
She insists snappers have descended on her five-year-old son James Wilkie's school, leaving her embarrassed to face other parents. She even claims James, her son with actor husband Matthew Broderick, now covers his face when posing for family photos.
Parker tells New York magazine, "(It's a) culture of thuggery.
"I feel very ashamed. I feel like I'm, like, the town trollop. It makes me feel ashamed of my work. And I'm not. But I'm attached to this culture now in a way that it's kind of vulgar.
"And I feel cheapened. And I feel like I'm cheapening the school, like I'm bringing dirt; like I'm bad for the neighbourhood."
See Also
Subscribe to:
Posts (Atom)